Mostrando 3 resultados de: 3
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusUse of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
ArticleAbstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreaPalabras claves:Autores:Caballero A., Calderón N.A., Cepeda M., Diáz Y., Estevez D., Hidalgo C.J., La O Y., Leon K., Lorenzo G., Luaces P.L.o., Martín Y., Mazorra Z., Oyarzábal J.P.A., Pérez Y., Ramos-Suzarte M., Saavedra Hernández D., Santiago W., Tania Crombet, Valenzuela-Silva C.M., Viñet O.Fuentes:scopusSafety of racotumomab in the treatment of patients with non-small cell lung cancer
ArticleAbstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary toPalabras claves:Adverse events, Clinical trial, Non-small cell lung cancer, RacotumomabAutores:Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.Fuentes:scopus